The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression

Xiaolei Wei, Meng Xu, Yongqiang Wei, Fen Huang, Tong Zhao, Xiangzhao Li, Ru Feng, B. Hilda Ye

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort.

Original languageEnglish (US)
Article number34
JournalJournal of Hematology and Oncology
Volume7
Issue number1
DOIs
StatePublished - Apr 16 2014

Fingerprint

Protein Isoforms
Survival
Therapeutics
Rituximab

Keywords

  • Bone marrow involvement
  • CD44 variant isoforms
  • CHOP
  • DLBCL
  • Prognosis
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Molecular Biology

Cite this

The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression. / Wei, Xiaolei; Xu, Meng; Wei, Yongqiang; Huang, Fen; Zhao, Tong; Li, Xiangzhao; Feng, Ru; Ye, B. Hilda.

In: Journal of Hematology and Oncology, Vol. 7, No. 1, 34, 16.04.2014.

Research output: Contribution to journalArticle

Wei, Xiaolei ; Xu, Meng ; Wei, Yongqiang ; Huang, Fen ; Zhao, Tong ; Li, Xiangzhao ; Feng, Ru ; Ye, B. Hilda. / The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression. In: Journal of Hematology and Oncology. 2014 ; Vol. 7, No. 1.
@article{2d00bae219304dc0b4b39031bc3655e1,
title = "The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression",
abstract = "Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort.",
keywords = "Bone marrow involvement, CD44 variant isoforms, CHOP, DLBCL, Prognosis, Rituximab",
author = "Xiaolei Wei and Meng Xu and Yongqiang Wei and Fen Huang and Tong Zhao and Xiangzhao Li and Ru Feng and Ye, {B. Hilda}",
year = "2014",
month = "4",
day = "16",
doi = "10.1186/1756-8722-7-34",
language = "English (US)",
volume = "7",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression

AU - Wei, Xiaolei

AU - Xu, Meng

AU - Wei, Yongqiang

AU - Huang, Fen

AU - Zhao, Tong

AU - Li, Xiangzhao

AU - Feng, Ru

AU - Ye, B. Hilda

PY - 2014/4/16

Y1 - 2014/4/16

N2 - Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort.

AB - Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort.

KW - Bone marrow involvement

KW - CD44 variant isoforms

KW - CHOP

KW - DLBCL

KW - Prognosis

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84899931212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899931212&partnerID=8YFLogxK

U2 - 10.1186/1756-8722-7-34

DO - 10.1186/1756-8722-7-34

M3 - Article

C2 - 24739401

AN - SCOPUS:84899931212

VL - 7

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 34

ER -